6Zhang J,Zhang Y,Shi Y,et al.Population pharmacokinetic and pharacodynamic modeling of norvancomycin[J].Eur J Clin Microbiol Infect Dis,2008,27(4):275-284.
7Leader WC,Chandler M.Castiglia M.Pharmacikinetics op itimization of vancomycin therapy[J].Clin Pharmacokinet,1995,28:327-342.
8Barmerman TL, Hancock GA, Tenover FC, et al. Pulsedfield gel electrophoresis as a replacement for bacteriophage typing of Staphylococcus aureus [J]. J Clin Microbiol, 1995, 33 (3): 551-555.
9Dalla Costa LM, Reynolds PE, Souza HA, et al. Characterization of a divergentn vand-type resistance element from the first glycopeptide-resistant strain of Enterococcus faecium isolated in Brazil [J]. Antimicrob Agents Chemother, 2000, 44 (12) : 3444-3446.
10Arias CA, Reyes J, Zuniga M, et al. Multicentre surveillance of antimicrobial resistance in Enterococci and Staphylococci from Colombian hospitals, 2001-2002[J]. Andmicrob Chemother, 2003, 51 (1): 59-68.
3Leroy S,Gervaix A. Procalcitonin:a key marker in children with urinary tract infection[J]. Adv Urol, 2011,2011 (2) : 397618.
4Neha Nanda and Manisha Jut hani-Mehta. Novel biomarkers for the diagnosis of urinary tract infection: a systematic revew[J].Bi- omark Insights,2009,4(5) :111-121.
5Wacogne ID. Acute serum procalcitonin levels may indicate pyelo- nephritis in children with febrile UTIs[J]. Arch Dis Child Educ Pratt Ed,2010,95(5) :165 -171.
